MX2024006267A - Anticuerpos anti ngf y usos de los mismos - Google Patents
Anticuerpos anti ngf y usos de los mismosInfo
- Publication number
- MX2024006267A MX2024006267A MX2024006267A MX2024006267A MX2024006267A MX 2024006267 A MX2024006267 A MX 2024006267A MX 2024006267 A MX2024006267 A MX 2024006267A MX 2024006267 A MX2024006267 A MX 2024006267A MX 2024006267 A MX2024006267 A MX 2024006267A
- Authority
- MX
- Mexico
- Prior art keywords
- ngf
- canine
- methods
- provides novel
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/055—Fusion polypeptide containing a localisation/targetting motif containing a signal for localisation to secretory granules (for exocytosis)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/48—Nerve growth factor [NGF]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163282590P | 2021-11-23 | 2021-11-23 | |
| US202263383173P | 2022-11-10 | 2022-11-10 | |
| PCT/US2022/080428 WO2023097275A1 (en) | 2021-11-23 | 2022-11-23 | Anti-ngf antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024006267A true MX2024006267A (es) | 2024-11-08 |
Family
ID=86540392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024006267A MX2024006267A (es) | 2021-11-23 | 2022-11-23 | Anticuerpos anti ngf y usos de los mismos |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20250011410A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4436602A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024543139A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240141160A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022397400A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3238769A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024006267A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023097275A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116096741B (zh) | 2020-07-10 | 2024-10-18 | 因外泰克斯公司 | 用于延长治疗剂在猫科动物中的半衰期的组合物和使用方法 |
| KR20250137204A (ko) | 2022-12-27 | 2025-09-17 | 인베티엑스 인코포레이티드 | 신생아 fc 수용체(fcrn)에 대한 결합이 변경된 폴리펩타이드 및 사용 방법 |
| AU2023415535A1 (en) | 2022-12-27 | 2025-07-10 | Invetx, Inc. | Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use |
| WO2025245092A1 (en) * | 2024-05-20 | 2025-11-27 | Invetx, Inc. | Anti-ngf antibodies and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1575517T3 (da) * | 2002-12-24 | 2012-05-14 | Rinat Neuroscience Corp | Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme |
| US8082436B2 (en) | 2008-07-08 | 2011-12-20 | Dell Products L.P. | Enhanced UEFI framework layer |
| SG187592A1 (en) * | 2010-07-23 | 2013-03-28 | Univ Boston | Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery |
| ES2665954T3 (es) * | 2010-08-19 | 2018-04-30 | Zoetis Belgium S.A. | Anticuerpos anti-NGF y su uso |
| BR112020017701A2 (pt) * | 2018-03-12 | 2020-12-29 | Zoetis Services Llc | Anticorpos anti-ngf e métodos dos mesmos |
| SG11202104120VA (en) * | 2018-10-31 | 2021-05-28 | Delinia Inc | Multivalent regulatory t cell modulators |
| TW202237648A (zh) * | 2020-11-18 | 2022-10-01 | 美商開拓免疫醫療公司 | 抗marco抗體及其用途 |
-
2022
- 2022-11-23 US US18/712,401 patent/US20250011410A1/en active Pending
- 2022-11-23 AU AU2022397400A patent/AU2022397400A1/en active Pending
- 2022-11-23 KR KR1020247020568A patent/KR20240141160A/ko active Pending
- 2022-11-23 JP JP2024531129A patent/JP2024543139A/ja active Pending
- 2022-11-23 EP EP22899552.8A patent/EP4436602A4/en active Pending
- 2022-11-23 WO PCT/US2022/080428 patent/WO2023097275A1/en not_active Ceased
- 2022-11-23 CA CA3238769A patent/CA3238769A1/en active Pending
- 2022-11-23 MX MX2024006267A patent/MX2024006267A/es unknown
-
2023
- 2023-07-06 US US18/348,173 patent/US12110322B2/en active Active
-
2024
- 2024-01-23 US US18/420,296 patent/US12378308B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023097275A1 (en) | 2023-06-01 |
| AU2022397400A1 (en) | 2024-06-06 |
| US20250011410A1 (en) | 2025-01-09 |
| EP4436602A4 (en) | 2026-07-08 |
| US20240010717A1 (en) | 2024-01-11 |
| US20240199727A1 (en) | 2024-06-20 |
| CA3238769A1 (en) | 2023-06-01 |
| US12378308B2 (en) | 2025-08-05 |
| JP2024543139A (ja) | 2024-11-19 |
| KR20240141160A (ko) | 2024-09-25 |
| US12110322B2 (en) | 2024-10-08 |
| EP4436602A1 (en) | 2024-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2206728T1 (en) | Methods for the treatment of bone cancer pain by administration of an antagonist nerve growth factor | |
| ATE548388T1 (de) | An den interleukin-4-rezeptor bindende antikörper | |
| EA201992590A1 (ru) | Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения | |
| EA200600254A1 (ru) | Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf | |
| MX2022013945A (es) | Nuevas proteinas de union a repeticiones de anquirina y sus usos. | |
| UA102775C2 (uk) | Спосіб лікування болю із застосуванням анти-ngf антитіла | |
| WO2004004633A3 (en) | Use of tnfalpha antibodies and another drug | |
| MX364874B (es) | Anticuerpos de il-6 y uso de los mismos. | |
| AR082390A1 (es) | Terapia de combinacion para tratar el cancer que comprende un inhibidor del igf-1r y un inhibidor de akt | |
| AR104812A1 (es) | Combinaciones terapéuticas y métodos para tratar neoplasias | |
| Li et al. | Inhibition of chemokine CX3CL1 in spinal cord mediates the electroacupuncture-induced suppression of inflammatory pain | |
| MX2022013894A (es) | Anticuerpos neutralizantes que se unen a la proteina s del sars-cov-2. | |
| MX2022011856A (es) | Anticuerpos de proteina tirosina cinasa especifica de musculo humano (musk) terapeuticos. | |
| MX2023004020A (es) | Anticuerpos anti-ngf y métodos para su uso. | |
| BR112022026533A2 (pt) | Anticorpo anti-fxi/fxia, fragmento de ligação do mesmo, e antígenos e uso farmacêutico do mesmo | |
| MX2023002106A (es) | Anticuerpos fgfr3 y metodos de uso. | |
| MX2025011192A (es) | Fragmentos de fc que se unen a fcrn y metodos de uso | |
| Salazar‐Degracia et al. | Reduced lung cancer burden by selective immunomodulators elicits improvements in muscle proteolysis and strength in cachectic mice | |
| Luo et al. | Glucocorticoid receptor contributes to electroacupuncture-induced analgesia by inhibiting Nav1. 7 expression in rats with inflammatory pain induced by complete freund's adjuvant | |
| BRPI0416467A (pt) | ácido nucléico purificado, célula hospedeira, proteìna purificada, anticorpo, fragmento fab, e, métodos para induzir a produção de tnf alfa, para tratar um paciente, e para triagem para inibidores da il-32 | |
| ZA202106627B (en) | Treatment of headache using anti-cgrp antibodies | |
| PH12020550066A1 (en) | METHOD FOR TREATING TNFa-RELATED DISEASE | |
| BR112023026111A2 (pt) | Anticorpo anti-cd40, fragmento de ligação ao antígeno e uso médico do mesmo | |
| ZA202205813B (en) | Trpv1 epitopes and antibodies | |
| RU2015147913A (ru) | Антитело против рецептора эпидермального фактора роста |